The discovery that thalidomide and its analogues work by inducing the degradation of transcription factors demonstrated both that protein degradation is a viable mechanism of action for therapeutic small molecules, and that it could be used to target transcription factors, which are undruggable by both biologics and traditional inhibitors.
BOSTON Researchers presented data at The Liver Meeting 2019 and in Nature this week demonstrating that bacteriophages targeted to specific members of the microbiome could be useful in fighting two different liver diseases.
BOSTON – Researchers presented data at The Liver Meeting 2019 and in Nature this week demonstrating that bacteriophages targeted to specific members of the microbiome could be useful in fighting two different liver diseases.
BOSTON In a late-breaking oral presentation on the last day of The Liver Meeting 2019, Durect Corp. reported results from its phase IIa trial of DUR-928 for the treatment of alcoholic hepatitis. All 19 patients enrolled in the study survived for 28 days after treatment with DUR-928 , and all but two responded to the drug as measured by Lille scores, which is used for predicting risk of death.
BOSTON – For diagnosing nonalcoholic steatohepatitis (NASH), liver biopsy is "the reference standard," Dean Hum, president of Genfit Corp., told BioWorld MedTech. "I'm not going to call it the gold standard."
Patients undergoing transcatheter aortic valve implant may need a pacemaker after the TAVR device, but a new study suggests that right bundle branch block may predict the need for pacing. The data may have implications for device selection as some devices are seen as less likely to trigger the need for a pacemaker, a development that may move the needle in the robust but increasingly competitive market for TAVR.